Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

Science

First published in Diabetes, Obesity and Metabolism on 2014 Mar.
Diabetes Obes Metab. 2014 Mar;16(3):215-22. doi: 10.1111/dom.12182. Epub 2013 Aug 19.

Authors: Macha S, Mattheus M, Halabi A, Pinnetti S, Woerle HJ, Broedl UC

Download full article as Pdf file:

Pdf File

REACHING OUT IS EASY AND FAST – LET’S TALK

Prof. Dr. Thomas Forst

Chairman of the Executive Board
located at CRS Mannheim

LET’S TALK SCIENCE

+49 621 150 45 – 0

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management

LET’S TALK BUSINESS

+49 621 150 45 – 0

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in subjects with renal impairment.

Read more

REACHING OUT IS EASY AND FAST – LET’S TALK

You May Also Like

Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.

Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.

The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.